TipRanks
Go Ultimate55% OFF

XP Chemistries AB (XPC) AI Stock Analysis

SE:XPC

XP Chemistries AB

(Nasdaq OMX AB:XPC)

Select Model
Rating:38Underperform
Price Target:SEK 0.14â–¼(-11.73% Downside)
Action:downgraded
Date:10/28/26

The overall score is very low, driven primarily by severe financial distress. The company is burning through its cash reserves with deeply negative operating and free cash flow, and it has no clear path to profitability. Technical trends reinforce this weakness, with the stock trading below all major moving averages and exhibiting bearish momentum. The debt-free balance sheet provides a temporary buffer but is rapidly eroding. The negative P/E ratio and lack of dividends further confirm the high-risk, speculative nature of the investment.

Positive Factors
Debt-free balance sheetThe absence of reported debt limits solvency pressure and avoids interest obligations that could further burden a loss-making business. This gives XP Chemistries greater financial flexibility to pursue scaling efforts and withstand operating volatility over the next several quarters.
Negative Factors
Persistent deep lossesPersistent negative net and operating results show that the current revenue base is insufficient to cover the company’s cost structure. Continued losses can erode equity, constrain reinvestment capacity, and keep the business dependent on additional funding until operating scale improves.

XP Chemistries AB (XPC) vs. iShares MSCI Sweden ETF (EWD)

-40%-30%-20%-10%0%10%20%SE:XPC-24.44%EWD+13.33%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
SEK 53.53M
Dividend Yield
―
Average Volume (3M)
288.74K
Price to Earnings (P/E)
-4.4
Beta (1Y)
0.12
Revenue Growth
―
EPS Growth
―
Country
Sweden
Employees
2
Sector
General
Sector Strength
55
Industry
Chemicals

XP Chemistries AB Business Overview & Revenue Model

Company Description

As a biotechnology company, XP Chemistries AB specializes in the development and production of forest-derived capsaicin and its related compounds. Its diverse offerings include ingredients for animal nutrition, components for cosmetic formulations, h...

How the Company Makes Money

null

XP Chemistries AB Financial Statement Overview

Summary

Financial performance is critically weak. The income statement shows persistent and deep operating losses with a TTM EBIT margin of -37.5% and declining revenue. The cash flow score is alarmingly low at 12, as the company is burning cash rapidly with negative free cash flow of SEK 12.3 million. The only mitigating factor is a debt-free balance sheet, but equity is eroding. The overall financial health is precarious.

Income Statement

18Very Negative

Balance Sheet

65Positive

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue320.05K327.39K283.94K663.68K1.06M279.39K
Gross Profit116.40K127.68K328.97K335.61K488.98K149.56K
EBITDA-10.28M-9.05M-7.52M-8.70M-8.50M-5.01M
Net Income-9.56M-8.52M-7.13M-8.04M-7.92M-4.55M
Balance Sheet
Total Assets33.90M38.07M22.72M27.20M30.65M34.39M
Cash, Cash Equivalents and Short-Term Investments9.71M15.23M2.15M7.83M15.20M21.40M
Total Debt000000
Total Liabilities1.77M1.13M1.16M1.51M1.58M3.09M
Stockholders Equity32.14M36.94M21.56M25.69M29.07M31.30M
Cash Flow
Free Cash Flow-12.34M-9.18M-8.53M-11.41M-11.80M-8.13M
Operating Cash Flow-11.68M-8.85M-7.69M-9.08M-9.85M-4.99M
Investing Cash Flow-1.30M-332.30K-834.96K-2.33M-1.95M-6.31M
Financing Cash Flow22.47M22.26M2.85M4.04M5.60M32.70M

XP Chemistries AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.16

Price Trends

50DMA0.18Negative
100DMA0.17Negative
200DMA0.18Negative

Market Momentum

MACD-0.00Negative
RSI50.29Neutral
STOCH75.27Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XPC, the sentiment is Negative. The current price of 0.16 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.18, and below the 200-day MA of 0.18, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 50.29 is Neutral, neither overbought nor oversold. The STOCH value of 75.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XPC.

XP Chemistries AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:XPC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:PCATSE:PCAT65NeutralSEK 14.87M4.56――-17.14%88.76%
SE:IMPCSE:IMPC56NeutralSEK 323.02M-12.36――6.10%51.80%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:ENZYSE:ENZY44NeutralSEK 551.01M-12.24――-2.36%23.44%
SE:NEXAMSE:NEXAM41NeutralSEK 258.28M-12.35-9.37%―-4.57%-15.20%
SE:CLBIOSE:CLBIO39UnderperformSEK 371.09M-28.83――54.37%52.22%
SE:XPCSE:XPC38UnderperformSEK 53.53M-4.36――――

* General Sector Average

Performance Comparison

0%100%200%SE:XPCSE:NEXAMSE:ENZYSE:IMPCSE:CLBIOSE:PCATDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
SE:XPC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:XPCXP Chemistries AB0.17-0.06-26.72%
SE:NEXAMNexam Chemical Holding AB2.52-0.60-19.23%
SE:ENZYEnzymatica AB2.270.3216.41%
SE:IMPCImpact Coatings AB3.071.66117.27%
SE:CLBIOCorline Biomedical AB14.20-5.75-28.82%
SE:PCATPhotocat A/S2.48-2.32-48.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026